Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
Caris Life Sciences (NASDAQ: CAI) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026.
Rhea-AI Summary
Caris Life Sciences (NASDAQ: CAI) announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. A live webcast will begin at 3:30 p.m. CT (4:30 p.m. ET) to discuss results, with a replay posted on the company investor relations website shortly after the call.
Details
News Market Reaction – CAI
On Apr 20, the day this news came out, CAI closed 0.43% above the previous close.
Data tracked by StockTitan Argus for the Apr 20 session.
Key Figures
- Earnings release date
- May 7, 2026
- Scheduled first quarter 2026 financial results
- Webcast time (CT)
- 3:30 p.m. CT
- Scheduled earnings webcast start time
- Webcast time (ET)
- 4:30 p.m. ET
- Corresponding Eastern Time for webcast
- Publication date
- April 20, 2026
- Earnings date announcement release
Previous Earnings date Reports
-
Announced date and webcast details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Caris Life Sciences will host a live webcast at 3:30 p.m. CT (4:30 p.m. ET) to discuss the financial results.
Webcast Details:
Date: Thursday, May 7, 2026
Time: 3:30 p.m. CT (4:30 p.m. ET)
Live Webcast: https://edge.media-server.com/mmc/p/6iwr2xf8/
A replay of the webcast will be available shortly after the conclusion of the call on the Investor Relations section of the Caris Life Sciences website at CarisLifeSciences.com.
About Caris Life Sciences
Caris Life Sciences® (Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Genome, Whole Exome and Whole Transcriptome Sequencing), advanced AI and machine learning, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies and high-performance computing provides a differentiated platform for developing the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with a vision to realize the potential of precision medicine to improve the human condition. Headquartered in
Caris Life Sciences Media:
Corporate Communications
CorpComm@CarisLS.com
214.294.5606
Investor Relations:
IR@CarisLS.com
917.689.3511
View original content to download multimedia:https://www.prnewswire.com/news-releases/caris-life-sciences-to-report-first-quarter-2026-financial-results-on-may-7-2026-302746471.html
SOURCE Caris Life Sciences
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.